Massachusetts Pharmacists Association

09/08/2026

Although clinical data clearly demonstrate the benefits, safety, and effectiveness of vaccines, myths, misconceptions, fears, and concerns about adverse effects still reduce vaccination rates. Frontline healthcare providers, such as pharmacists, can use effective patient-education strategies to recognize and use evidence-based data to counter misinformation and overcome obstacles.https://www.mdpi.com/2076-393X/14/2/154

09/07/2026

09/05/2026

Measles transmission from infected people with prior vaccination is uncommon but possible, a systematic review and meta-analysis found. Investigators identified documented transmission across healthcare facilities, schools, and community settings. The findings reinforce the need to consider vaccinated cases during public-health outbreak investigations https://www.tandfonline.com/doi/full/10.1080/14760584.2026.2708188

09/04/2026

The FDA approved enlicitide (Lipfendra), the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, for adults with high cholesterol, including heterozygous familial hypercholesterolemia. In two trials, once-daily enlicitide reduced LDL cholesterol by 56% and 59% versus placebo when added to maximally tolerated statin therapy, offering patients an alternative to existing injectable PCSK9 treatments https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol

09/03/2026

Developed by the American Heart Association in 2023, the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations estimate 10-year and 30-year risk for total cardiovascular disease (CVD), including atherosclerotic CVD (ASCVD) and heart failure (HF). It is the first risk tool to combine cardiovascular, kidney, and metabolic health measures to guide primary prevention-focused treatment decisions. https://professional.heart.org/en/guidelines-and-statements/prevent-calculator

09/02/2026

The FDA approved centanafadine (Simtriyo), a once-daily extended-release stimulant, for attention-deficit/hyperactivity disorder (ADHD) in adults and children aged 6 years and older weighing at least 20 kg. Centanafadine inhibits norepinephrine, dopamine, and serotonin reuptake. Trials showed significant symptom improvement, but pediatric labeling includes a boxed warning about suicidal thoughts and behaviors
https://www.simtriyo.com/

09/01/2026

2026 AHA/ACC Dyslipidemia Guidelines https://www.ahajournals.org/doi/epub/10.1161/CIR.0000000000001457

08/31/2026

Strong medication safety practices depend on consistency and accountability. We're sharing this Med Safety Tip from the Alliance for Patient Medication Safety to support safer patient care in Massachusetts

08/30/2026

The FDA has approved furosemide injection via an autoinjector to treat edema in adults with heart failure or chronic kidney disease. https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-fda-approval-furoscix-readyflowtm-first-and